DAX24.339 -1,3%Est505.912 -1,0%MSCI World4.343 -0,1%Top 10 Crypto10,05 +0,8%Nas26.247 +1,7%Bitcoin68.038 -0,2%Euro1,1784 +0,5%Öl100,5 -2,7%Gold4.717 +0,7%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 NVIDIA 918422 Allianz 840400 Infineon 623100 SAP 716460 Siemens Energy ENER6Y Lufthansa 823212 Commerzbank CBK100 AMD (Advanced Micro Devices) 863186 NEL ASA A0B733 Amazon 906866 Deutsche Telekom 555750 Intel 855681 Microsoft 870747 RENK RENK73
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Nasdaq und S&P-500 In Rekordlaune -- DAX geht mit Verlusten ins Wochenende -- Commerzbank übertrifft Erwartungen in Q1 -- Rheinmetall, Nintendo, SoftBank, AMD, Innodata, NEL im Fokus
Top News
DAX in KW 19: Diese Aktien gehörten zu den Gewinnern und Verlierern DAX in KW 19: Diese Aktien gehörten zu den Gewinnern und Verlierern
NVIDIA-Gespräche beflügeln die Vision, aber drücken den Kurs: SoftBank-Aktie unter Druck NVIDIA-Gespräche beflügeln die Vision, aber drücken den Kurs: SoftBank-Aktie unter Druck
Suche...
Jetzt kostenlos
bei finanzen.net anmelden
Watchlists & Musterdepots Tools & integriertes Trading Newsletter, Trading-Desk uvm.
Schon einen Account? Anmelden
Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

PTC Therapeutics Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
62,87 EUR +8,13 EUR +14,85 %
BMN
73,74 USD -0,08 USD -0,11 %
nachbörslich
BTT
finanzen.net zero
PTC Therapeutics jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.4,70 Mrd. EUR

KGV9,76Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1W0MW

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS69366J2006

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolPTCT

PTC Therapeutics Aktien News

DatumMeistgelesen
PR NewswirePTC Therapeutics Provides Key Regulatory Updates
PR NewswirePTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
PR NewswirePTC Therapeutics to Participate at Upcoming Investor Conferences
PR NewswirePTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswirePTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results
PR NewswireCHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna™ (ataluren) Following Re-examination Procedure
PR NewswirePTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 42nd Annual J.P. Morgan Healthcare Conference
PR NewswirePTC Therapeutics to Participate at 42nd Annual J.P. Morgan Healthcare Conference
PR NewswirePTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswirePTC Therapeutics Provides Updates on Translarna™ Regulatory Activities
PR NewswirePTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswirePTC Therapeutics Provides Corporate Update and Reports Third Quarter Financial Results
PR NewswirePTC Therapeutics Announces Evrysdi® Royalty Agreement with Royalty Pharma for Up To $1.5 Billion
PR NewswirePTC Therapeutics to Host Conference Call to Discuss Third Quarter 2023 Financial Results 
PR NewswirePTC Announces Further Strategic Prioritization and Associated Reduction in Workforce
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
PR NewswireCHMP Delivers Opinion on Translarna™ for Conversion to Full Authorization
PR NewswirePTC Therapeutics' 2023 STRIVE Awards Program Funds Initiatives Supporting the Duchenne Patient Community
PR NewswireAustralian Patient Advocacy Organization Named a Recipient of PTC Therapeutics' 2023 STRIVE™ Award for Duchenne Muscular Dystrophy
PR NewswirePTC Therapeutics to Participate at Upcoming Investor Conferences
PR NewswirePTC Therapeutics to Present Recent Data for Sepiapterin at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium
PR NewswirePTC Therapeutics Provides Corporate Update and Reports Second Quarter Financial Results
PR NewswireCHMP Recommends Evrysdi® for Babies Under Two Months Old with Spinal Muscular Atrophy
PR NewswirePTC Therapeutics to Host Conference Call to Discuss Second Quarter 2023 Financial Results
PR NewswirePTC Therapeutics Co-Founder Allan Jacobson, Ph.D., Awarded 2023 Gruber Genetics Prize
PR NewswirePTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswirePTC Therapeutics Appoints Experienced Healthcare Finance Strategist Pierre Gravier as Chief Financial Officer
PR NewswirePTC Therapeutics Announces Virtual Presentation on Phenylketonuria (PKU) and Sepiapterin
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
PR NewswirePTC Therapeutics Announces Results from MIT-E Clinical Trial of Vatiquinone for the Treatment of Mitochondrial Disease Associated Seizures
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
PR NewswirePTC Therapeutics Shares Positive Interim Data from PIVOT-HD Clinical Trial in Huntington's Disease Patients
PR NewswirePTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
PR NewswirePTC Therapeutics to Participate at Upcoming Investor Conferences
PR NewswirePTC Therapeutics Announces Topline Results from Vatiquinone MOVE-FA Registration-Directed Trial
PR NewswirePTC Therapeutics Announces Strategic Pipeline Prioritization
PR NewswirePTC Therapeutics Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients
PR NewswirePTC Therapeutics Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients

PTC Therapeutics News

PTC Therapeutics News: auf dieser Seite finden Sie alle PTC Therapeutics News und Nachrichten zur PTC Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch PTC Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um PTC Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.